Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?

QIAGEN N.V.’s (QGEN) solid potential in the molecular diagnostics area is poised to help it grow in the coming quarters. The company continues to progress with its test menu expansion, building a solid foundation to achieve its long-term targets. Strategic collaborations with Eli Lilly are helping it develop and market its existing and potential products. Meanwhile, the adverse impact of macroeconomic challenges as well as intense competition remain a concern for QIAGEN’s operations.In the past year, this Z ...